ICD-10's Implementation Effects Category B Billing
The director of Health Economics and Reimbursement for the Regulatory & Clinical Research Institute (RCRI) discusses the repercussions of implementing ICD-10.
ICD-10's Implementation Effects Category B Billing
In a comment to Applied Clinical Trials, Monica M. Schultz, M.S., Director of Health Economics and Reimbursement for Minneapolis-based Regulatory & Clinical Research Institute (RCRI), said, "ICD-10 will have an enormous impact to hospitals and their billing structure. It's a huge change that hospitals and insurers have been anticipating for several years, but not necessarily preparing for, because the timing of the change was uncertain. The new coding system appears more logical, but expect a painful transition.”
Schultz anticipates that ICD-10 will impact clinical trials via billing for Category B devices. However, she believes difficulties may be minimized via proper training. Here are her tips: “At the initiation visit, schedule time with the billing manager to provide a list of procedures included in the protocol and associated billing codes. Sponsors may also consider providing a toll-free "hotline" to answer questions from the site. All reimbursement reference materials should be reviewed by the sponsor's legal department, as it should be made clear it is the site's responsibility to verify appropriate codes with the insurer.”
Visit RCRI's Web site at http://www.rcri-inc.com/ Schultz co-authored an article regarding “Medicare’s Proposed Cost-Effectiveness Criteria Revisited: Considerations for Clinical Trials Design,” scheduled to appear in the May issue and the Web site of Applied Clinical Trials.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
